2021年8月27日 · In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in...

2020年8月28日 · In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or...

When compared with placebo, empagliflozin reduced the composite risk of cardiovascular death or hospitalization for heart failure, decreased total hospitalizations for heart failure, and improved health status and functional class.

2023年8月25日 · The EMPEROR-Reduced trial showed that empagliflozin is superior to placebo in improving HF outcomes among patients with symptomatic stable HFrEF (EF ≤40%) on excellent baseline GDMT, irrespective of diabetes status.

2020年5月15日 · Among patients with heart failure and diabetes mellitus, empagliflozin therapy resulted in increased natriuresis as monotherapy and demonstrated a clinically meaningful synergistic effect when combined with a loop diuretic. This enhanced natriuresis persisted over the 14-day study period, resulting in a reduction in plasma volume.

2018年12月6日 · Relative reductions in risk of cardiovascular death, all-cause mortality, 3-point MACE and hospitalization for heart failure with empagliflozin versus placebo were consistent in patients with and without prior myocardial infarction and/or stroke and across subgroups by TIMI Risk Score for Secondary Prevention at baseline (P>0.05 for randomized ...

2021年1月27日 · To the Editor: In the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction (EMPEROR-Reduced), Packer et al. (Oct. 8 issue) 1 found that empagliflozin...

2022年2月28日 · We designed the present study to evaluate the effects of empagliflozin on three fundamental goals of care in patients hospitalized for acute heart failure: improvement of survival, reduction of...

2024年11月22日 · The European Union and the United States of America have recently approved empagliflozin (EMPA) for the treatment of all adults with symptomatic chronic heart failure (CHF). This approval is based on the drug’s ability to reduce the risk of cardiovascular events, including hospitalizations for HF and cardiovascular death, regardless of the ...

2023年4月18日 · EMPA-VISION (Assessment of Cardiac Energy Metabolism, Function and Physiology in Patients With Heart Failure Taking Empagliflozin) is a prospective, randomized, double-blind, placebo-controlled, mechanistic trial that enrolled 72 symptomatic patients with chronic HF with reduced ejection fraction (HFrEF; n=36; left ventricular ejection fraction ...